AbbVie Inc (ABBV)vsLigand Pharmaceuticals Incorporated (LGND)
ABBV
AbbVie Inc
$288.84
-0.98%
HEALTHCARE · Cap: $521.11B
LGND
Ligand Pharmaceuticals Incorporated
$307.02
-4.87%
HEALTHCARE · Cap: $6.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 22621% more annual revenue ($66.01B vs $290.54M). LGND leads profitability with a 67.9% profit margin vs 15.7%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
LGND
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$288.84
$132.00 premium
Margin of Safety
-6.3%
Fair Value
$174.97
Current Price
$307.02
$132.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Keeps 68 of every $100 in revenue as profit
Revenue surging 33.7% year-over-year
Earnings expanding 825.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : LGND
The strongest argument for LGND centers on Profit Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 67.9% and operating margin at 13.5%. Revenue growth of 33.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : LGND
The primary concerns for LGND are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while LGND is a growth play — different risk/reward profiles.
LGND carries more volatility with a beta of 1.01 — expect wider price swings.
LGND is growing revenue faster at 33.7% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 67/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ligand Pharmaceuticals Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?